Diphtheria, tetanus, and acellular pertussis antigens (DTaP/Tdap)

The adaptive immune system's response to diphtheria, tetanus, and acellular pertussis antigens is the biological mechanism underlying DTaP and Tdap vaccinations. These vaccines contain inactivated toxoids from Corynebacterium diphtheriae and Clostridium tetani, as well as purified components of Bordetella pertussis such as pertussis toxoid and filamentous hemagglutinin (CDC, 2020). Upon administration, these antigens are processed by dendritic cells and presented via MHC molecules to T-cell receptors, initiating a cascade that leads to B-cell activation and the secretion of neutralizing IgG antibodies (StatPearls, 2023). This process establishes immunological memory, allowing for a rapid and robust response upon subsequent exposure to the actual pathogens. Although not a single molecular target, this antigenic complex is the therapeutic focus for preventing respiratory and neurological complications associated with these bacterial infections. Safety profiles are generally favorable, though local reactions and rare systemic events like anaphylaxis can occur (WHO, 2017).

Other names

DTaPTdapDTPaDiphtheria-Tetanus-Pertussis vaccineTriple vaccine

Induction of active immunity by presenting inactivated toxoids and bacterial antigens to the adaptive immune system, stimulating B-cell differentiation into plasma cells that secrete neutralizing antibodies and the formation of memory B and T cells.